LIGAND PHARMACEUTICAL INC (LGNXZ)
USD 0.0
(18.18%)
USD 0.0
(18.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 131.31 Million USD | -33.09% |
| 2022 | 196.24 Million USD | -18.75% |
| 2021 | 241.54 Million USD | 29.57% |
| 2020 | 186.41 Million USD | 54.98% |
| 2019 | 120.28 Million USD | -52.17% |
| 2018 | 251.45 Million USD | 78.21% |
| 2017 | 141.1 Million USD | 29.48% |
| 2016 | 108.97 Million USD | 51.53% |
| 2015 | 71.91 Million USD | 11.43% |
| 2014 | 64.53 Million USD | 31.78% |
| 2013 | 48.97 Million USD | 56.02% |
| 2012 | 31.38 Million USD | 4.5% |
| 2011 | 30.03 Million USD | 27.61% |
| 2010 | 23.53 Million USD | -39.55% |
| 2009 | 38.94 Million USD | 42.56% |
| 2008 | 27.31 Million USD | 111.84% |
| 2007 | 12.89 Million USD | -90.85% |
| 2006 | 140.96 Million USD | -20.18% |
| 2005 | 176.6 Million USD | 117.72% |
| 2004 | 81.11 Million USD | -42.53% |
| 2003 | 141.14 Million USD | 46.05% |
| 2002 | 96.64 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 41.53 Million USD | 34.07% |
| 2024 Q1 | 30.97 Million USD | 10.24% |
| 2023 Q1 | 43.97 Million USD | -12.71% |
| 2023 Q3 | 32.86 Million USD | 24.66% |
| 2023 Q2 | 26.36 Million USD | -40.05% |
| 2023 Q4 | 28.1 Million USD | -14.5% |
| 2023 FY | 131.31 Million USD | -33.09% |
| 2022 Q2 | 57.41 Million USD | 25.66% |
| 2022 Q3 | 66.08 Million USD | 15.1% |
| 2022 Q1 | 45.69 Million USD | -36.95% |
| 2022 FY | 196.24 Million USD | -18.75% |
| 2022 Q4 | 50.38 Million USD | -23.77% |
| 2021 Q1 | 55.15 Million USD | -70.42% |
| 2021 Q3 | 64.83 Million USD | -23.43% |
| 2021 Q2 | 84.67 Million USD | 53.54% |
| 2021 Q4 | 72.47 Million USD | 11.78% |
| 2021 FY | 241.54 Million USD | 29.57% |
| 2020 Q2 | 41.42 Million USD | 24.91% |
| 2020 FY | 186.41 Million USD | 54.98% |
| 2020 Q3 | 41.84 Million USD | 1.03% |
| 2020 Q4 | 186.41 Million USD | 345.47% |
| 2020 Q1 | 33.16 Million USD | 0.0% |
| 2019 Q2 | 24.98 Million USD | -42.54% |
| 2019 FY | 120.28 Million USD | -52.17% |
| 2019 Q1 | 43.48 Million USD | 0.0% |
| 2019 Q3 | 24.8 Million USD | -0.72% |
| 2018 Q3 | 45.66 Million USD | -49.29% |
| 2018 Q2 | 90.04 Million USD | 60.34% |
| 2018 FY | 251.45 Million USD | 78.21% |
| 2018 Q1 | 56.15 Million USD | 0.0% |
| 2017 Q2 | 27.99 Million USD | -4.35% |
| 2017 FY | 141.1 Million USD | 29.48% |
| 2017 Q3 | 33.37 Million USD | 19.22% |
| 2017 Q1 | 29.26 Million USD | 0.0% |
| 2016 Q2 | 18.41 Million USD | -37.88% |
| 2016 Q1 | 29.64 Million USD | 0.0% |
| 2016 Q3 | 21.61 Million USD | 17.38% |
| 2016 FY | 108.97 Million USD | 51.53% |
| 2015 FY | 71.91 Million USD | 11.43% |
| 2015 Q3 | 17.7 Million USD | -3.89% |
| 2015 Q2 | 18.41 Million USD | 26.13% |
| 2015 Q1 | 14.6 Million USD | 0.0% |
| 2014 Q3 | 14.97 Million USD | 41.15% |
| 2014 FY | 64.53 Million USD | 31.78% |
| 2014 Q1 | 15.95 Million USD | 0.0% |
| 2014 Q2 | 10.6 Million USD | -33.53% |
| 2013 Q3 | 13 Million USD | 35.75% |
| 2013 Q2 | 9.58 Million USD | -17.78% |
| 2013 Q1 | 11.65 Million USD | 0.0% |
| 2013 FY | 48.97 Million USD | 56.02% |
| 2012 FY | 31.38 Million USD | 4.5% |
| 2012 Q2 | 5.74 Million USD | 1.88% |
| 2012 Q3 | 6.37 Million USD | 11.02% |
| 2012 Q1 | 5.63 Million USD | 0.0% |
| 2011 Q1 | 3.89 Million USD | 0.0% |
| 2011 Q2 | 7.46 Million USD | 91.56% |
| 2011 FY | 30.03 Million USD | 27.61% |
| 2011 Q3 | 5.74 Million USD | -23.07% |
| 2010 FY | 23.53 Million USD | -39.55% |
| 2010 Q3 | 7.8 Million USD | 33.64% |
| 2010 Q2 | 5.83 Million USD | -2.01% |
| 2010 Q1 | 5.95 Million USD | 0.0% |
| 2009 Q1 | 9.47 Million USD | 0.0% |
| 2009 FY | 38.94 Million USD | 42.56% |
| 2009 Q2 | 7.59 Million USD | -19.81% |
| 2009 Q3 | 7.9 Million USD | 4.04% |
| 2008 Q3 | 5.24 Million USD | 9.24% |
| 2008 Q2 | 4.8 Million USD | -1.44% |
| 2008 Q1 | 4.87 Million USD | 0.0% |
| 2008 FY | 27.31 Million USD | 111.84% |
| 2007 FY | 12.89 Million USD | -90.85% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | 1.41 Million USD | 0.0% |
| 2007 Q3 | 5.47 Million USD | 288.58% |
| 2006 Q1 | 50.95 Million USD | 0.0% |
| 2006 Q2 | 48.44 Million USD | -4.92% |
| 2006 Q3 | 36.7 Million USD | -24.23% |
| 2006 FY | 140.96 Million USD | -20.18% |
| 2005 FY | 176.6 Million USD | 117.72% |
| 2005 Q2 | 45.79 Million USD | 23.83% |
| 2005 Q1 | 36.98 Million USD | 0.0% |
| 2005 Q3 | 44.75 Million USD | -2.28% |
| 2004 FY | 81.11 Million USD | -42.53% |
| 2004 Q1 | 36.61 Million USD | 0.0% |
| 2004 Q2 | 40.46 Million USD | 10.51% |
| 2003 FY | 141.14 Million USD | 46.05% |
| 2003 Q2 | 29.12 Million USD | 25.96% |
| 2003 Q1 | 23.12 Million USD | 0.0% |
| 2003 Q3 | 31.28 Million USD | 7.41% |
| 2002 Q3 | 25.26 Million USD | 0.0% |
| 2002 FY | 96.64 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | - USD | -Infinity% |
| Allstar Health Brands, Inc. | - USD | -Infinity% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 195.23 Million USD | 32.742% |
| Café Serendipity Holdings, Inc. | 44.55 Thousand USD | -294623.376% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | - USD | -Infinity% |
| HealthWarehouse.com, Inc. | 20.28 Million USD | -547.398% |
| MedGen, Inc. | 1.05 USD | -12506095138.095% |
| Omni Health, Inc. | 4.69 Million USD | -2696.716% |
| Oxford Investments Holdings Inc. | 61.16 Thousand USD | -214581.119% |
| Pineapple, Inc. | 381.89 Thousand USD | -34285.294% |
| ScripsAmerica, Inc. | 30.85 Million USD | -325.589% |